Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data
Bio Expo
Champignondagen
  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
Generative AI Reshapes the Disparate Health Technology Assessment Landscape
  • Press Releases

Generative AI Reshapes the Disparate Health Technology Assessment Landscape

  • The Pharma Data
  • March 12, 2025

Generative AI Revolutionizes Health Technology Assessment Landscape: Trinity Life Sciences Enhances HTA Vision Trinity Life Sciences, a leading provider of strategy, insights, and analytics for the life sciences industry, has…

Read MoreGenerative AI Reshapes the Disparate Health Technology Assessment Landscape
Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases
  • Research

Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases

  • The Pharma Data
  • March 12, 2025

Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases Seismic Therapeutic, Inc., a machine learning-driven immunology company, has announced a significant milestone in its journey toward developing transformative…

Read MoreSeismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases
Cellino and Matricelf Partner to Advance Personalized Spinal Cord Injury Treatments
  • Press Releases

Cellino and Matricelf Partner to Advance Personalized Spinal Cord Injury Treatments

  • The Pharma Data
  • March 12, 2025

Cellino and Matricelf Partner to Scale Personalized Spinal Cord Injury Treatments Cellino and Matricelf (TASE: MTLF) announced today a groundbreaking global collaboration aimed at accelerating the biomanufacturing of personalized spinal…

Read MoreCellino and Matricelf Partner to Advance Personalized Spinal Cord Injury Treatments
Nosis Biosciences Partners with Daiichi Sankyo on RNA Medicines
  • Business

Nosis Biosciences Partners with Daiichi Sankyo on RNA Medicines

  • The Pharma Data
  • March 12, 2025

Nosis Biosciences and Daiichi Sankyo Partner to Advance RNA Medicines Nosis Biosciences, an AI-driven biotechnology company specializing in RNA therapeutics for challenging cell types, has announced a Research Collaboration and…

Read MoreNosis Biosciences Partners with Daiichi Sankyo on RNA Medicines
Tenpoint Therapeutics Names Carol Kearney as CCO
  • News

Tenpoint Therapeutics Names Carol Kearney as CCO

  • The Pharma Data
  • March 12, 2025

Tenpoint Therapeutics Names Carol Kearney as Chief Commercial Officer Tenpoint Therapeutics Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company dedicated to pioneering treatments that rejuvenate vision in the aging eye, has…

Read MoreTenpoint Therapeutics Names Carol Kearney as CCO
Twist Bioscience Offers Express Clonal Genes at No Extra Cost for Researchers
  • Press Releases

Twist Bioscience Offers Express Clonal Genes at No Extra Cost for Researchers

  • The Pharma Data
  • March 12, 2025

Twist Bioscience Announces Expedited Delivery for Academic Orders of Twist Express Genes at No Additional Cost Twist Bioscience Corporation (NASDAQ: TWST), a leading mid-cap growth and value equity company operating…

Read MoreTwist Bioscience Offers Express Clonal Genes at No Extra Cost for Researchers
Agenus Reports Q4 2024 Results, Strengthens BOTBAL Program
  • Business

Agenus Reports Q4 2024 Results, Strengthens BOT/BAL Program

  • The Pharma Data
  • March 12, 2025

Agenus Reports Q4 2024 Results, Strengthens BOT/BAL Program Agenus Reports Q4 and Full-Year 2024 Financial and Operational Results, Implements Strategic Cost Reductions to Enhance Sustainability of BOT/BAL Program Agenus Inc.…

Read MoreAgenus Reports Q4 2024 Results, Strengthens BOT/BAL Program
Ayrmid Pharma Ltd., a pioneering company in cell therapy
  • Business

RoslinCT & Ayrmid Pharma Plan Strategic Partnership for Omisirge® Manufacturing

  • The Pharma Data
  • March 12, 2025

RoslinCT and Ayrmid Pharma Ltd. Plan Strategic Partnership for Omisirge® Manufacturing Ayrmid Pharma Ltd., a pioneering company in cell therapy focused on transforming cells into powerful therapeutics, and RoslinCT, a…

Read MoreRoslinCT & Ayrmid Pharma Plan Strategic Partnership for Omisirge® Manufacturing
NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products
  • Press Releases

NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products

  • The Pharma Data
  • March 12, 2025

NationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products NationsBenefits®, a leading provider of supplemental benefits and healthcare fintech solutions, has announced a strategic partnership with…

Read MoreNationsBenefits® Partners with TS Emporium to Expand Access to Culturally Relevant Health Products
Noramco Group Invests $25M in Halo Pharma for Sterile Injectables
  • News

Noramco Group Invests $25M in Halo Pharma for Sterile Injectables

  • The Pharma Data
  • March 11, 2025

Noramco Group Invests $25M in Halo Pharma for Sterile Injectables The Noramco Group Invests $25 Million in Halo Pharma’s Whippany Facility to Establish Sterile Injectable Manufacturing The Noramco Group, a…

Read MoreNoramco Group Invests $25M in Halo Pharma for Sterile Injectables
Care Access Acquires Brazil-Based Clinical Research Center CEMEC
  • Research

Care Access Acquires Brazil-Based Clinical Research Center CEMEC

  • The Pharma Data
  • March 11, 2025

Care Access Acquires Brazil-Based Clinical Research Center CEMEC Care Access, a globally recognized healthcare and clinical research organization, has announced the successful acquisition of Centro Multidisciplinar de Estudos Clínicos (CEMEC),…

Read MoreCare Access Acquires Brazil-Based Clinical Research Center CEMEC
WAINZUA (Eplontersen) Receives EU Approval for Hereditary ATTR Amyloidosis Treatment
  • Regulatory

WAINZUA (Eplontersen) Receives EU Approval for Hereditary ATTR Amyloidosis Treatment

  • The Pharma Data
  • March 11, 2025

WAINZUA (Eplontersen) Receives EU Approval for Hereditary ATTR Amyloidosis Treatment Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that WAINZUA (eplontersen), developed in collaboration with AstraZeneca, has been approved by the…

Read MoreWAINZUA (Eplontersen) Receives EU Approval for Hereditary ATTR Amyloidosis Treatment
PrevNext
UK Biotech Day
Global Clinical
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Celltrion Unveils KRW 1.2 Trillion Expansion of Songdo Drug Substance Facilities, Boosting Total Capacity to 570,000 Liters
  • Eylea 8 mg Secures Approval in Japan for a Third Retinal Disease Indication
  • Bristol Myers Squibb Highlights Camzyos Data in oHCM at ACC 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.